Recent Conferences
October 14, 2010
Fall Forum
July 8, 2010
Summer Forum
April 15, 2010
Spring Forum
October 14, 2009
Accelerating High-Value Healthcare
September 16, 2009
Next Steps Toward a Robust Comparative Effectiveness Research Enterprise
July 20, 2009
Establishing a National Health Insurance Exchange
June 11, 2009
Federal Strategies for Promoting Affordable Biologics: Follow-On Biologic Competition
April 29, 2009
Implementing Bundled Payments for Health Care Services
November 24, 2008
Medicare Delivery System Reform
October 2, 2008
Specialty Pharmaceuticals: Policy Solutions for Encouraging Access and Affordability
July 16, 2008
Managing Specialty Pharmaceuticals
June 4, 2008
"Road Testing" Electronic Medical Records
April 30, 2008
Innovation Workgroup
April 10, 2008
Payment and Delivery System Reform
November 29, 2007
Comparative Effectiveness Congressional Briefing
November 27, 2007
Overview of Cost Management Strategies
October 24, 2007
Coverage With Evidence Development
October 2, 2007
Value-Based Payment for Medical Technologies
September 18, 2007
Personalized Medicine Conference
July 25, 2007
Comparative Effectiveness: Stakeholder Perspectives
April 11, 2007
Post Marketing Surveillance
February 14, 2007
Comparative Effectiveness Research: Congressional Briefing
November 30, 2006
Comparative Effectiveness Forum
October 12, 2006
Coverage Policy in an Era of Personalized Medicine
July 13, 2006
Pharmaceutical Benefit Management
May 1, 2006
Methodology Standards
April 4, 2006
Technology Assessment
October 3, 2005
Promoting Appropriate Utilization
April 1, 2005
Evidence-Based Health Care System
July 16, 2004
Correcting Underuse in Health Care
October 2, 2008
Specialty Pharmaceuticals: Policy Solutions for Encouraging Access and Affordability
On July 16, 2008 The Health Industry Forum held a conference on Specialty Pharmaceuticals that examined key market trends, specialty drug management strategies in Medicare and commercial insurers, and key social policy issues affecting access to and affordability of specialty products. This follow up meeting discussed potential policy solutions for the following issues identified during the July meeting:
1. Independent and overlapping structure of medical and pharmacy benefits limits the potential for integrated medical management.
2. Physician financial incentives often conflict with the most appropriate choice of specialty pharmaceuticals
3. Uncertainty about the effectiveness of specialty pharmaceuticals - particularly for off-label uses - creates challenges for designing rational payment and coverage policies
4. High coinsurance requirements for specialty pharmaceuticals (e.g., Tier 4) creates extreme financial burdens for beneficiaries who require expensive drug therapies
The objective of this meeting was to develop a refined set of policy options that provide an acceptable basis for continued discussion among a broad range of stakeholders.
Presentations:
Coordinating Medical and Pharmacy Benefits for More Effective Program Management
Dan Mendelson and Lauren Barnes, Avalere Health
Designing Physician Financial Incentives for Appropriate Care
Charles Lee Blansett, Senior Vice President, MattsonJack DaVinci
Designing Payment Policies to Promote Appropriate Utilization
Sharon Levine, MD, Associate Executive Director, Kaiser Permanente
Addressing Social Tradeoffs of Coinsurance for Specialty Pharmaceuticals
Donald W. Moran, President, The Moran Company
